CNBC January 8, 2025
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.
The U.S. Food and Drug Administration wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments.
That’s according to the agency’s official tally of new treatments not previously approved or marketed in the U.S. The total drugs cleared dipped slightly from 55 in 2023, but there were several firsts and other notable medications that the agency gave a green light last year.
That includes the first-ever treatment for metabolic dysfunction-associated steatohepatitis (MASH,) a common and potentially deadly liver disease that affects millions worldwide. The drug, Rezdiffra,...
Today's Sponsors
Today's Sponsor